APA (7th ed.) Citation

Y, C., F, K., PS, G., G, N., Q, G., I, I., . . . CG, M. (2023). The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood, 142(7), 629. https://doi.org/10.1182/blood.2022017813

Chicago Style (17th ed.) Citation

Y, Chang, et al. "The Orally Bioavailable GSPT1/2 Degrader SJ6986 Exhibits In vivo Efficacy in Acute Lymphoblastic Leukemia." Blood 142, no. 7 (2023): 629. https://doi.org/10.1182/blood.2022017813.

MLA (9th ed.) Citation

Y, Chang, et al. "The Orally Bioavailable GSPT1/2 Degrader SJ6986 Exhibits In vivo Efficacy in Acute Lymphoblastic Leukemia." Blood, vol. 142, no. 7, 2023, p. 629, https://doi.org/10.1182/blood.2022017813.